

# Metenova's Magnetic Mixers – An Important and Critical Component in The Emergence of New And Revolutionary Pharmaceutical Drugs

➡ **Metenova is a Swedish company** boasting strong growth and profitability. Their extensive portfolio includes magnet-powered mixers, a central component for global pharmaceutical companies manufacturing liquid, sterile pharmaceuticals.

– We possess technologies and knowledge unique to a highly interesting niche market. There are great opportunities for future growth, due to the development of new, so-called biological drugs, such as Mab, recombinants and mRNA vaccines, says Johan Westman, Metenova CEO.

Metenova has quickly established itself as a leading technology innovator with a strong offer. Their portfolio consists of mixers customized for various types of applications, based on the company's patented technologies. Their clients are prominent pharmaceutical companies as well as businesses manufacturing biological drugs.

– Due to an increasing share of biological drugs, combined with a huge share of traditional drugs – so called blockbusters – and the rapid growth of the Chinese market following a shift to defined drugs, there is considerable underlying growth potential for Metenova's products and skills, says Johan Westman.

## **The Mixing process Is Becoming More Complex**

The Metenova product portfolio of magnetic mixers is based on patented Metenova technology. The technology has grown more advanced over the years, mirroring the development of pharmaceuticals in general. One of Metenova's mixer technologies is

completely layer-less, hovering in a magnetic field. For all injected, liquid drugs, it's extremely important that all syringes share the exact same concentration of active substances. This is what makes the mixing process so crucial.

– Since we broke the code to our DNA, there has been a paradigm shift in the pharmaceutical business. In essence, it means that we are far better at developing truly efficient and targeted biological substances today, says Lennart Myhrberg, VP Marketing.

These new targeted therapies bring completely new drugs and treatment options, which might even cure rheumatism, Alzheimer's, various types of cancer, Malaria or AIDS.

– Several variants of the Covid vaccine, as well as the vaccine against cervical cancer, are examples of these products. This means that the mixing required for producing these drugs is becoming more and more delicate. For instance, it's important that no proteins are destroyed during production, Johan says.



*Johan Westman, VD*



*Lennart Myhrberg, Vice President Marketing*

## **The Skilled West Coast**

The core of Metenova's business can be found in their product innovation teams. The headquarters are located on the Swedish West Coast, in Mölndal, something both Johan and Lennart consider a big advantage.

– In Mölndal exists a cluster with excellent resources for this kind of product development. We have a great exchange with the local universities and have built an extensive network of production specialists, Lennart emphasizes.

Metenova's latest product is a mixer meant for single use, a production method that has proven to be key to the very large global production capacity of Covid vaccines.

– It means we've developed a completely new technology and thus have entered a new phase of our innovational journey. We're convinced this will result in us claiming additional market shares in our niche, Johan concludes.

## **FAKTA**

Metenova is a global supplier of products and solutions for producing aseptic and sterile pharmaceuticals. Metenova has extensive experience of the high demands within product development, manufacturing, and sales in this area. Their innovative and patented mixing technologies have enjoyed great success in the global pharmaceutical industry. The company has a turnover of approximately 150 million SEK, and a profit margin exceeding 20 percent.